Read More

Pharvaris’ Promising Oral Treatment Solutions For Treating Swollen Blood Vessels – Analyst Sees 35% Upside

Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ: PHVS), noting that the company stands out as one of the players with their strategy to develop and advance oral therapeutic options in both the acute and prophylactic settings for hereditary angioedema (HAE).

PHVS

Read More

FDA Strikes Off Coherus BioSciences’ New Injector Biosimilar Treatment For Cancer Patients

The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of Udenyca (pegfilgrastim-cbqv), solely due to an ongoing review of inspection 

AMGN